Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cell Procurement

Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?

Bone Marrow Transplantation volume 43, pages 301–305 (2009)Cite this article

Abstract

CD34+ cell dose calculations are usually based on actual body weight (ABW). We have shown that ideal body weight (IBW) may provide a better basis for this in a small population of patients with hematologic malignancies. This was studied further in 514 myeloma autografts. The CD34+ cell doses (106/kg) by IBW and ABW were 1.37–39.36 (median 6.03) and 1.15–29.67 (median 4.84), respectively. IBW-based cell doses correlated slightly better with engraftment than ABW-based doses (higher r2): 0.5 × 109/l neutrophils 0.83 versus 0.82, 1.0 × 109/l neutrophils 0.78 versus 0.77, 20 × 109/l platelets 0.54 versus 0.53 and 50 × 109/l platelets 0.57 versus 0.55. When outliers (hematologic recovery in <8 or >16 days) were excluded, the findings were similar: 0.5 × 109/l neutrophils 0.85 versus 0.84, 1.0 × 109/l neutrophils 0.85 versus 0.84, 20 × 109/l platelets 0.86 versus 0.85 and 50 × 109/l platelets 0.85 versus 0.84. CD34+ cell doses based on IBW as well as ABW significantly affected engraftment when analyzed separately as continuous variables. However, when analyzed together, only the dose based on IBW retained significance. We conclude that calculation of CD34+ cell numbers for autotransplantation should be based on IBW.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Waples JM, Moreb JS, Sugrue M, Belanger G, Kubilis P, Lynch JW et al. Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 1999; 23: 867–873.

    Article  CAS  PubMed  Google Scholar 

  2. Singhal S, Powles R, Sirohi B, Kulkarni S, Treleaven J, Mehta J . CD34+ cell dose based upon ideal body weight (IBW) is a better predictor of transplant-related mortality (TRM) and disease-free survival (DFS) than that based upon actual body weight (ABW). Blood 2002; 100: 1667.

    Google Scholar 

  3. Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 2003; 31: 861–864.

    Article  CAS  PubMed  Google Scholar 

  4. Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman MS et al. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 2004; 33: 161–164.

    Article  CAS  PubMed  Google Scholar 

  5. Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt O et al. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 553–557 erratum in: Bone Marrow Transplant 2006; 37: 1067).

    Article  CAS  PubMed  Google Scholar 

  6. Maclean PS, Parker AN, McQuaker IG, Clark AD, Farrell E, Douglas KW . Body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant 2007; 40: 665–669.

    Article  CAS  PubMed  Google Scholar 

  7. Topcuoglu P, Akcaglayan Soydan E, Ekiz F, Ayyildiz E, Dalva K, Ozcan M et al. To calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight. Transfus Apher Sci 2007; 36: 275–280.

    Article  PubMed  Google Scholar 

  8. Mehta J, Singhal S . High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007; 40: 1101–1114.

    Article  CAS  PubMed  Google Scholar 

  9. Gidron A, Verma A, Doyle M, Boggio L, Evens A, Gordon L et al. Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies? Bone Marrow Transplant 2005; 35: 243–246.

    Article  CAS  PubMed  Google Scholar 

  10. Egan K, Singh V, Gidron A, Mehta J . Correlation between serum lactate dehydrogenase and stem cell mobilization. Bone Marrow Transplant 2007; 40: 931–934.

    Article  CAS  PubMed  Google Scholar 

  11. Devine DJ . Gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650–655.

    Article  Google Scholar 

  12. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I . The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213–226.

    Article  CAS  PubMed  Google Scholar 

  13. Verma A, Pedicano J, Trifilio S, Singhal S, Tallman M, Winter J et al. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant 2004; 33: 715–719.

    Article  CAS  PubMed  Google Scholar 

  14. Ali MY, Oyama Y, Monreal J, Winter J, Tallman M, Gordon LI et al. Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 × 109/l neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplant 2002; 30: 749–752.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. V Singh and J Krishnamurthy: These two authors contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology/Oncology, Northwestern University Medical School, Chicago, IL, USA

    V Singh, J Krishnamurthy, S Duffey, R Meagher, M Villa, J Monreal, A Evens, O Frankfurt, J Altman, L Gordon, M Tallman, S Williams, J Winter, S Singhal & J Mehta

Authors
  1. V Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Krishnamurthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Duffey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Meagher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Villa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Monreal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Evens
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. O Frankfurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Altman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Tallman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. S Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. J Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Mehta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, V., Krishnamurthy, J., Duffey, S. et al. Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?. Bone Marrow Transplant 43, 301–305 (2009). https://doi.org/10.1038/bmt.2008.322

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.322

Keywords

This article is cited by

Search

Advanced search

Quick links